MedTrace Logo

A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial

NCT03642691 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2022-12-09

No results posted yet for this study

Summary

The clinical trial is no longer enrolling and is currently closing and Prometic will continue to provide Plasminogen (Human) under a treatment protocol to subjects in the United States (US) with hypoplasminogenemia requiring plasminogen replacement therapy who completed the End of Study visit in the following Prometic-sponsored clinical trials: 2002C011G, 2002C013G, 2002C016G, 2002C017G and 2002C019G.

Conditions

  • Hypoplasminogenemia

Interventions

BIOLOGICAL

Ryplazim

Plasminogen IV replacement therapy

Sponsors & Collaborators

  • Prometic Biotherapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Jeremy Lorber, MD · Tower Hematology, Oncology

  • Heather McDaniel, MD · Vanderbilt Childrens Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03642691 on ClinicalTrials.gov